The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Mass spectrometry monitoring with the Binding Site EXENT analyzer in multiple myeloma
Martin Kaiser, MD, FRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, discusses the Binding Site EXENT analyzer, a mass spectrometry-based tool for monitoring monoclonal proteins in multiple myeloma. He highlights its greater sensitivity and personalized measurement of paraproteins compared with conventional methods, with potential applications in monitoring deep remission, treatment-free intervals and earlier detection of disease resurgence. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
